Lung Cancer
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
24: Lung cancer as an 'acute presentation' in acute unselected medical admissions at a district general hospital (audit at Kings Mill hospital, November 2013–May 2014)
2015
-
Evaluating improvement in patient-reported dyspnea and pulmonary function tests (PFTs) in patients with malignant pleural mesothelioma (MPM): An analysis as part of the 448-patient randomized pemetrexed plus cisplatin versus cisplatin trial
2005
-
Long-term survival update from the randomized phase III study of pemetrexed plus cisplatin vs cisplatin in patients with malignant pleural mesothelioma (MPM)
2005
-
P-126 Activation of tyrosine kinase receptors and intracellular signal mediators in NSCLC tumors
2005
-
P-252 Interim report: A phase III randomized double blindchemoprevention trial of selenium supplementation in persons with resected stage I non small cell lung cancer
2005
-
P-936 Use of an algorithm to aid determination of causality in early clinical trials of lung cancer using targeted therapy
2005
-
Phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer (NSCLC)
2005
-
Reporting on consistency of clinical practice with lung cancer guidelines: A clinical monograph by Cancer Care Ontario
2005
-
Updated multiple regression analysis of prognostic variables for survival in malignant pleural mesothelioma (MPM): Observations from a phase III study of pemetrexed plus cisplatin versus cisplatin and evolution of the regression model
2005
-
Use of forced vital capacity (FVC) measurement for the clinical management of malignant pleural mesothelioma (MPM): Observations from the pemetrexed plus cisplatin versus cisplatin study
2005
-
A study examining epidermal growth factor receptor, p53, and Bcl-2 expression in patients with locally advanced squamous cell carcinoma of the head and neck treated with concomitant chemoradiotherapy
2004
-
ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis.
161:9-17.
2021
-
Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer.
160:127-135.
2021
-
The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.
160:136-151.
2021
-
Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada.
157:40-47.
2021
-
Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model.
151:108-109.
2021
-
A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226.
143:1-11.
2020
-
Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
134:259-267.
2019
-
Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219.
133:48-55.
2019
-
Ultrasonographic characteristics of lymph nodes as predictors of malignancy during endobronchial ultrasound (EBUS): A systematic review.
126:97-105.
2018
-
Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.
120:142-148.
2018
-
A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.
104:65-69.
2017
-
Biennial lung cancer screening in Canada with smoking cessation—outcomes and cost-effectiveness.
101:98-103.
2016
-
Chemoradiotherapy versus radiotherapy alone in elderly patients with stage III non-small cell lung cancer: A systematic review and meta-analysis.
99:180-185.
2016
-
Temporal trends in the incidence and relative survival of non-small cell lung cancer in Canada: A population-based study.
90:8-14.
2015
-
MicroRNA expression profiling of thymic epithelial tumors.
85:197-204.
2014
-
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.
74:481-485.
2011
-
The function of IGF-IR in NNK-mediated lung tumorigenesis.
71:11-18.
2011
-
Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer.
52:327-332.
2006
-
Taxanes as first-line therapy for advanced non-small cell lung cancer: A systematic review and practice guideline.
50:355-374.
2005
-
P-125 p-38 MAPK, Erk and Akt expression and activation in NSCLCtumors; Subcellular distribution and radiographic response to radiotherapy.
49:S147-S148.
2005
-
P-526 Phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer (NSCLC).
49:S255-S256.
2005
-
Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer.
48:47-57.
2005
-
Is postoperative radiotherapy for radically resected NSCLC detrimental and therefore unnecessary?.
46:379-380.
2004
-
Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer.
46:361-368.
2004
-
Response to issues raised by Dr. Debevec ?Is postoperative radiotherapy for radically resected NSCLC detrimental and therefore unnecessary??.
46:381-381.
2004
-
15 years single center experience with surgical resection of the superior vena cava for non-small cell lung cancer.
45:357-363.
2004
-
Postoperative radiotherapy in stage II or IIIA completely resected non-small cell lung cancer: a systematic review and practice guideline.
44:1-11.
2004
-
Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer.
43:223-240.
2004
-
O-66 Impact of whole brain radiation therapy (WBRT) and motexafin gadolinium (MGd) on neurologic and neurocognitive progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a randomized phase III trial.
41:S22-S22.
2003
-
P-465 Differences in baseline characteristics between non-small cell lung cancer (NSCLC) and breast cancer (BrCa) patients with brain metastases.
41:S208-S209.
2003
-
Phase II study of pegylated liposomal doxorubicin HCI (caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer.
41:S232-S232.
2003
-
Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy.
39:1-13.
2003
-
Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables.
37:235-240.
2002
-
Bcl-2 is an independent prognostic factor and adds to a biological model for predicting outcome in operable non-small cell lung cancer.
34:417-426.
2001
-
Towards a biological staging model for operable non-small cell lung cancer.
34:S83-S89.
2001
-
Gemzar and Navelbine in the treatment of patients with stage III b and IV non-small cell lung cancer. A phase II trial.
29:31-31.
2000
-
Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer.
29:169-177.
2000
-
Taxotere in malignant pleural mesothelioma. A phase II clinical trial.
29:19-19.
2000
-
Angiogenesis and non-small cell lung cancer.
27:81-100.
2000
-
Erratum to “The function of IGF-IR in NNK-mediated lung tumorigenesis” [Lung Cancer 71 (1) (2011) 11–18] - Lung Cancer
2016
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)